
The Genedrive MT-RNR1 ID Kit has potential benefits in identifying babies at risk of hearing loss from aminoglycoside due to the MT-RNR1 m.1555A>G variant, allowing for alternative antibiotics to be used instead. However, managing the risk of early access is important, including ensuring timely antibiotics, avoiding unnecessary use of alternative antibiotics, and confirming positive results. The economic evidence suggests cost-effectiveness, but upfront costs may be high. Data should be generated in centers with babies from different ethnicities to promote equality.
Recent Posts
Biopharma Ecosystem Competitiveness: Post-COVID Challenges and Opportunities
Biopharma Ecosystem Competitiveness in Global Race
A new EFPIA analysis compares bioph...
EMA Validation of ENHERTU Breast Cancer Treatment for Post-Neoadjuvant Therapy
EMA Validates ENHERTU Breast Cancer Treatment Variation
The European Medicines Agency (EMA) has validated a Type II Variation marketing authorization application for ENHERTU breast cancer treatment, specifically ENHERTU (trast...
NICE Updates Type 2 Diabetes Guidelines: Emphasizing Cardiorenal Protection with SGLT2 Inhibitors
Type 2 Diabetes Guidelines Reshape Initial Treatment
The latest Type 2 Diabetes Guidelines from NICE (National Institute for Health and Care Excellence), published on 18 February 2026 as an update to guideline NG28 ("Type 2 diabe...